Lung Cancer Trials Ask AI to find trials
UnknownNot applicableNCT03517332
Official study title

Circulating Tumor DNA Exposure in Peripheral Blood

Study summary

This is a prospective, multi-center, blinded feasibility study. The objective of this study is to test the feasibility of the detection of tumor DNA of a variety of tumors in peripheral blood using a novel process for the detection of circulating tumor DNA (ctDNA).

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedNot specified

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 20, 2018 · Source: ClinicalTrials.gov

Is enrollment open?Unknown

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Quantgene Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Quantgene Inc.
Interventions being studied
Not specified
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • This study will include subjects that are diagnosed with a malignancy (cohort 1\) and a negative cohort with subjects that have not been diagnosed with a malignancy (cohort 2).
  • Subjects of both cohorts must:
  • Be of age ≥ 18
  • Provide written consent for study participation
  • Subject of cohort 1 must:
  • Have a diagnosis of a malignancy in clinical stage 0 to IV including but not limited to: colon or rectal cancer, pancreatic and gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, bladder cancer, melanoma Subjects of cohort 2 must:
  • Meet the listed matching criteria
Reasons someone may not be able to joinExclusion criteria
  • Subjects of cohort 1 must not: Have been treated for above diagnosed malignancy
  • Subjects of cohort 2 must not:
  • Have been diagnosed/treated for a malignancy previously

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • University of Arizona Cancer CenterTucson, Arizona
  • Florida Hospital Celebration HealthCelebration, Florida
  • Orlando Health UF Health Cancer CenterOrlando, Florida
  • Premier Surgical OncologyCenterville, Ohio
  • Kettering Medical CenterDayton, Ohio
  • University Hospital of GenevaGeneva

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 20, 2018. Always confirm current availability with the study team.

View original record ↗